The pericardium is the layer that surrounds the heart. The pericardium has two layers that work to lubricate the heart, protect it, and prevent it from filling up with too much blood. When this layer ...
– ARCALYST® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively – – ARCALYST full-year 2023 net product revenue expected to be $190 - ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Regeneron announced that its Phase 3 study of Arcalyst (rilonacept injection) met its primary and secondary endpoints for the prevention of gout attacks. This trial, known as PRE-SURGE 1 (PREventative ...
Credit: Getty Images. Arcalyst is a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1. The Food and Drug Administration (FDA) has approved Arcalyst ® (rilonacept) ...
TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Earnings Call Insights: Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2025 Sanj Patel, CEO & Chairman of the Board, stated that "Year-to-date, in 2025, we've continued to execute and ...
(RTTNews) - Kiniksa Pharmaceuticals Ltd.'s (KNSA) flagship product Arcalyst has garnered widespread acclaim and acceptance since its launch in April 2021. With a growing adoption rate, the company has ...
Tarrytown, NY (August 11, 2008) – Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the publication of the results of three studies which supported the U.S. Food and Drug Administration ...
TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results